Minerva shares surge 18.46% premarket after announcing $200M financing and NDA plans.

Minerva Neurosciences (NASDAQ: NERV) surged 18.46% in premarket trading following the announcement of a $200 million financing deal and plans to submit a New Drug Application (NDA) for its lead candidate. The news, highlighted as the primary catalyst, directly aligns with the stock’s upward movement, signaling investor confidence in the company’s capital raise and regulatory progress. Other events, including debt analysis for unrelated entities (BVMF:BEEF3), a sports-related loss, and acquisitions by Minerva Bunkering, were irrelevant to the premarket rally of NERV.